Drugs for macular degeneration

(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is thought to bethe first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same scientists published early, six month outcomes of the same study, which also failed to show (Read more...)

Full Story →